31 January 2019
Visiongain has launched a new pharma report Global Pre-Filled Syringes Market Forecast 2019-2029: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors, Insulin Therapies, Rheumatoid Arthritis (RA) Therapies, Growth Hormones, Vaccines, PCSK9 Inhibitors.
The pre-filled syringes market has become more competitive in recent years as both syringe component suppliers and pharma companies develop product offerings to compete with established device makers. Rapid growth in this market will be due to the increasing burden of chronic disease, the launch of new biological drugs and biosimilars and pharma companies’ need for more complex drug delivery solutions including innovative pen injectors and autoinjectors.
The lead analyst of the report commented "The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.
Innovation, suitability for use with viscous and higher-volume drugs and designing products with usability in mind will help manufacturers in this market to differentiate their products and gain market share in an increasingly competitive environment."
Leading companies featured in the report include BD, Gerresheimer, Schott, SHL Group, Ypsomed and others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.